Sign in Sign up for free

Last updated: 15 June 2023 at 4:50pm EST

Tillman Gerngross Net Worth



Tillman Gerngross ALEC stock SEC Form 4 insiders trading

Tillman has made over 1 trades of the Alector stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of ALEC stock worth $2,000,000 on 20 November 2017.

The largest trade he's ever made was buying 200,000 units of Alector stock on 20 November 2017 worth over $2,000,000. On average, Tillman trades about 28,571 units every 0 days since 2017. As of 20 November 2017 he still owns at least 392,821 units of Alector stock.

You can see the complete history of Tillman Gerngross stock trades at the bottom of the page.





Tillman Gerngross biography

Dr. Tillman U. Gerngross Ph.D. serves as Chairman of the Board, Co-Founder of the Company. Dr. Gerngross is a founder, director, and executive officer of numerous biotechnology companies. He is a founder and currently serving as Chief Executive Officer and as a director of Adimab, LLC. He is also a founder and Chairman of the board of directors of Avitide, Inc. and a founder and the Chairman of the board of directors of Arsanis, Inc. Dr. Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006. Dr. Gerngross co-founded GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck & Company, Inc. Dr. Gerngross currently teaches in the departments of Biology and Chemistry, as well as at the School of Engineering at Dartmouth College, where he has taught since 1998. Dr. Gerngross attended the Technical University of Vienna, Austria, where he received a B.S. and M.S. in Chemical Engineering and a Ph.D. in Molecular Biology.

What is the salary of Tillman Gerngross?

As the Chairman of the Board and Co-Founder of Alector, the total compensation of Tillman Gerngross at Alector is $313,752. There are 9 executives at Alector getting paid more, with Arnon Rosenthal having the highest compensation of $6,854,340.



How old is Tillman Gerngross?

Tillman Gerngross is 56, he's been the Chairman of the Board and Co-Founder of Alector since 2013. There are 8 older and 9 younger executives at Alector. The oldest executive at Alector, Inc. is Louis Lavigne, 72, who is the Lead Independent Director.

What's Tillman Gerngross's mailing address?

Tillman's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Alector

Over the last 5 years, insiders at Alector have traded over $148,873,269 worth of Alector stock and bought 20,000 units worth $500,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Advisors Llc Orbi Med Capit..., and Terrance Mcguire. On average, Alector executives and independent directors trade stock every 17 days with the average trade being worth of $438,922. The most recent stock trade was executed by Marc Grasso on 3 September 2024, trading 7,297 units of ALEC stock currently worth $35,609.



What does Alector do?

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase Ib clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease; and 8 candidates in immuno-neurology/immuno-oncology field comprise ADP012, ADP016, ADP017, ADP023, ADP026, ADP122, ADP009, and ADP022. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.



What does Alector's logo look like?

Alector, Inc. logo

Alector executives and stock owners

Alector executives and other stock owners filed with the SEC include: